Literature DB >> 22330038

Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Andreas A Schnitzbauer1, Sven A Lang, Holger Goessmann, Silvio Nadalin, Janine Baumgart, Stefan A Farkas, Stefan Fichtner-Feigl, Thomas Lorf, Armin Goralcyk, Rüdiger Hörbelt, Alexander Kroemer, Martin Loss, Petra Rümmele, Marcus N Scherer, Winfried Padberg, Alfred Königsrainer, Hauke Lang, Aiman Obed, Hans J Schlitt.   

Abstract

OBJECTIVE: To evaluate a new 2-step technique for obtaining adequate but short-term parenchymal hypertrophy in oncologic patients requiring extended right hepatic resection with limited functional reserve.
BACKGROUND: Patients presenting with primary or metastatic liver tumors often face the dilemma that the remaining liver tissue may not be sufficient. Preoperative portal vein embolization has thus far been established as the standard procedure for achieving resectability.
METHODS: Two-staged hepatectomy was performed in patients who preoperatively appeared to be marginally resectable but had a tumor-free left lateral lobe. Marginal respectability was defined as a left lateral lobe to body weight ratio of less than 0.5. In the first step, surgical exploration, right portal vein ligation (PVL), and in situ splitting (ISS) of the liver parenchyma along the falciform ligament were performed. Computed tomographic volumetry was performed before ISS and before completion surgery.
RESULTS: The study included 25 patients with primary liver tumors (hepatocellular carcinoma: n = 3, intrahepatic cholangiocarcinoma: n = 2, extrahepatic cholangiocarcinoma: n = 2, malignant epithelioid hemangioendothelioma: n = 1, gallbladder cancer: n = 1 or metastatic disease [colorectal liver metastasis]: n = 14, ovarian cancer: n = 1, gastric cancer: n = 1). Preoperative CT volumetry of the left lateral lobe showed 310 mL in median (range = 197-444 mL). After a median waiting period of 9 days (range = 5-28 days), the volume of the left lateral lobe had increased to 536 mL (range = 273-881 mL), representing a median volume increase of 74% (range = 21%-192%) (P < 0.001). The median left lateral liver lobe to body weight ratio was increased from 0.38% (range = 0.25%-0.49%) to 0.61% (range = 0.35-0.95). Ten of 25 patients (40%) required biliary reconstruction with hepaticojejunostomy. Rapid perioperative recovery was reflected by normalization of International normalized ratio (INR) (80% of patients), creatinine (84% of patients), nearly normal bilirubin (56% of patients), and albumin (64% of patients) values by day 14 after completion surgery. Perioperative morbidity was classified according to the Dindo-Clavien classification of surgical complications: grade I (12 events), grade II (13 events), grade III (14 events, III a: 6 events, III b: 8 events), grade IV (8 events, IV a: 3 events, IV b: 5 events), and grade V (3 events). Sixteen patients (68%) experienced perioperative complications. Follow-up was 180 days in median (range: 60-776 days) with an estimated overall survival of 86% at 6 months after resection.
CONCLUSIONS: Two-step hepatic resection performing surgical exploration, PVL, and ISS results in a marked and rapid hypertrophy of functional liver tissue and enables curative resection of marginally resectable liver tumors or metastases in patients that might otherwise be regarded as palliative.

Entities:  

Mesh:

Year:  2012        PMID: 22330038     DOI: 10.1097/SLA.0b013e31824856f5

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  357 in total

Review 1.  Small for size liver remnant following resection: prevention and management.

Authors:  Rony Eshkenazy; Yael Dreznik; Eylon Lahat; Barak Bar Zakai; Alex Zendel; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 2.  Post-hepatectomy liver failure.

Authors:  Rondi Kauffmann; Yuman Fong
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 3.  The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach.

Authors:  Leonardo Patrlj; Mario Kopljar; Robert Kliček; Masa Hrelec Patrlj; Marijan Kolovrat; Mislav Rakić; Antonija Duzel
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

4.  ALPPS for patients with colorectal liver metastases: effective liver hypertrophy, but early tumor recurrence.

Authors:  Karl J Oldhafer; Marcello Donati; Robert M Jenner; Axel Stang; Gregor A Stavrou
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

Review 5.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 6.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

7.  First Left Hepatic Trisectionectomy Including Segment One with New Associated Liver Partition and Portal Vein Ligation with Staged Hepatectomy (ALPPS) Modification: How To Do It?

Authors:  Aiman Obed; Anwar Jarrad; Abdalla Bashir
Journal:  Am J Case Rep       Date:  2016-10-19

8.  Portal supply of segment IV of the liver based on CT-scan.

Authors:  Roxane Maurer; Michel Rivoire; Valéria Basso; Pierre Meeus; Patrice Peyrat; Aurélien Dupré
Journal:  Surg Radiol Anat       Date:  2016-10-18       Impact factor: 1.246

Review 9.  Portal vein embolization in extended liver resection.

Authors:  Nisha Narula; Thomas A Aloia
Journal:  Langenbecks Arch Surg       Date:  2017-05-31       Impact factor: 3.445

Review 10.  Role of associating liver partition and portal vein ligation for staged hepatectomy in colorectal liver metastases: a review.

Authors:  Kristina Hasselgren; Per Sandström; Bergthor Björnsson
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.